Citigroup’s Generate Biomedicines GENB Stock Holding History

Citigroup’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$516K	Buy	30,587 +28,343	+1,263%	+$386K	﹤0.01%	3880
2026 Q1	$28.1K	Buy	+2,244	New	+$27.4K	﹤0.01%	4728

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Citigroup's GENB Position: Q2 2026 in Review

Citigroup increased its Generate Biomedicines (GENB) stake by 1,263% in Q2 2026, buying an estimated $386K and bringing the position to 30,587 shares worth $516K. The position accounts for ﹤0.01% of the portfolio, ranked #3880.

Citigroup first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Citigroup held 30,587 shares of Generate Biomedicines worth $516K as of Q2 2026.
Citigroup bought 28,343 Generate Biomedicines shares in Q2 2026, an estimated $386K.
Generate Biomedicines made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3880 holding.
Citigroup first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.